Oncotalks hematology videos and news

ASCO 2019 Martin Bögemann

Martin Bögemann from the Universitätsklinikum Münster, Duitsland is commenting on "Boegemann M. et al. Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL. J Clin Oncol 37, 2019 (suppl; abstr 4574)", which her presented at ASCO 2019 in Chicago

Related items

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

Prof. Michelino DeLaurentiis, MD, PhD from the National Cancer Institute Fondazione G. Pascale is commenting on his abstract "DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041)", which was presented at ASCO 2019 in Chicago
ASCO , Kisqali Channel , Lithuania , Albania , Slovenia
00:03:07
ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

Prof. Piotr Rutkowski, MD, PhD from the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw is commenting on the abstract: "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507", which was presented at ASCO 2019 in Chicago
ASCO , Lithuania , Hungary , Albania
00:06:31